RBR-7jqpnw尚未招募3 期
Therapeutic effectiveness of COVID-19 convalescent plasma produced by HEMOPE: a multicenter, randomized and controlled clinical trial - PLAVID-TRIAL: Covid convalescent plasma - Clinical Trial
niversidade de Pernambuco0 个研究点开始时间: 2020年6月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 —（—）
入选标准
- •adults> 18 years with diagnosis of COVID – 19, who are hospitalized; and considered as having a condition that increases the risk of a worse prognosis: obesity; diabetes mellitus (DM); systemic arterial hypertension (SAH); chronic lung disease, obesity, diseases that alter immunity (AIDS, neoplasms or autoimmune diseases in immunosuppressive therapy, chronic liver disease.
排除标准
- •History of anaphylactic reaction related to blood transfusion.
研究者
相似试验
进行中（未招募）
1 期
Cure COVID: A study to compare the efficacy of GNS561 versus standard treatments in patients with SARS-CoV-2 (COVID-19) infection.COVID-19 infectionMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsEUCTR2020-002249-40-BGGenoscience Pharma120
招募中
3 期
Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this diseaseCOVID-19.COVID-19, virus identifiedU07.1IRCT20151228025732N53Semnan University of Medical Sciences12
暂停
2 期
Convalescent Antibody-Mediated Treatment of COVID-19 Infections in Patients with B-cell dysfunction, a Randomized Trial (COVID-Compromise Study).NL-OMON51203Academisch Medisch Centrum86
招募中
不适用
COVID-CompromiseNL-OMON25136AmsterdamUMC86
进行中（未招募）
1 期
An infusion of antibodies to COVID-19 for patients with B cell disorder, a randomized (randomized) study (COVID Compromise study).COVID-19 disease due to an infection with SARS-CoV2-virusEUCTR2020-006075-15-NLAmsterdam UMC86